New selective and potent class I HDAC inhibitor from Merck activates HIV latency ex vivo Aug. 28, 2019
Adaptimmune, Noile-Immune announce collaboration to develop next-generation SPEAR T-cell products Aug. 28, 2019
2-75, a novel enzalutamide-HDAC inhibitor hybrid with efficacy in models of prostate cancer Aug. 28, 2019
RSS